Greece’s Pharmaceutical Research & Technology Company (IFET S.A.) received the first 2,000 doses of a Covid-19 drug from companies Regeneron-Roche on Wednesday.
The drug, which is based on monoclonal antibodies, is becoming available in Greece for the first time by IFET, in the context of the country’s participation in EU’s program for the provision of this new therapy.
In an announcement by IFET, it was clarified that the goal of this treatment is to prevent the worsening of the disease, while treatment of patients will be based on criteria that are expected to be determined by relevant health authorities soon.
